Human polyomaviruses JC and BK in the urine of Brazilian children and adolescents vertically infected by HIV
Carregando...
Citações na Scopus
12
Tipo de produção
article
Data de publicação
2011
Título da Revista
ISSN da Revista
Título do Volume
Editora
FUNDACO OSWALDO CRUZ
Autores
SUCCI, Regina Celia de Menezes
CARMO, Fabiana Bononi do
GOUVEA, Aida de Fatima Barbosa
BELTRAO, Suenia Vasconcelos
SANTOS, Isabel Cristina Lopes dos
Citação
MEMORIAS DO INSTITUTO OSWALDO CRUZ, v.106, n.8, p.931-935, 2011
Resumo
The aim of this study was to characterize the urinary excretion of the BK (BKV) and JC (JCV) human polyomaviruses in a cohort of human immunodeficiency virus (HIV)-infected children and adolescents. One hundred and fifty-six patients were enrolled: Group I included 116 HIV-infected children and adolescents [median age = 11.4 years (y); range 1-22 y]; Group II included 40 non-HIV-infected healthy controls (median age = 11.37 y; range 7-16 y). Single urine samples from both groups were screened for the presence of JCV and BKV DNA by polymerase chain reaction at enrolment. The overall rate of JCV and BKV urinary excretion was found to be 24.4% and 40.4%, respectively (n = 156). Group I had urinary excretion of JCV and BKV in 27.6% and 54.3% of subjects, respectively. In contrast, Group II showed positive results for JCV in 17.5% of subjects and for BKV in 12.5% of subjects (p Pearson JCV = 0.20; p Pearson BKV < 0.0001). In Group I, there was no association between JCV/BKV shedding and age, gender or CD4 values. Patients with an HIV viral load < 50 copies/mL had a lower excretion of BKV (p < 0.001) and a trend of lower JCV excretion (p = 0.07). One patient in Group I (1/116, 0.9%) showed clinical and radiological features consistent with progressive multifocal leukoencephalopathy, suggesting that children with HIV/polyomavirus coinfection should be kept under surveillance.
Palavras-chave
HIV-1, child, adolescent, JC virus, BK virus, urine
Referências
- MAJOR EO, 1995, CURR OPIN NEUROL, V8, P184
- ARTHUR RR, 1989, J CLIN MICROBIOL, V27, P1174
- Agostini HT, 1997, P NATL ACAD SCI USA, V94, P14542, DOI 10.1073/pnas.94.26.14542
- Matos A, 2010, J MED VIROL, V82, P494, DOI 10.1002/jmv.21710
- MARKOWITZ RB, 1993, J INFECT DIS, V167, P13
- Behzad-Behbahani A, 2004, J CLIN VIROL, V29, P224, DOI 10.1016/S1386-6532(03)00155-0
- Lafon ME, 1998, J INFECT DIS, V177, P1502, DOI 10.1086/515305
- Antinori A, 2001, J NEUROVIROL, V7, P323, DOI 10.1080/13550280152537184
- Bratt G, 1999, AIDS, V13, P1071, DOI 10.1097/00002030-199906180-00010
- Centers for Disease Control and Prevention, 1994, MMWR-MORBID MORTAL W, V43, P1
- CHOWDHURY M, 1993, ONCOGENE, V8, P887
- CHOWDHURY M, 1992, J VIROL, V66, P7355
- Degener AM, 1997, MICROBIOLOGICA, V20, P115
- Drake AK, 2007, EUR J NEUROL, V14, P418, DOI 10.1111/j.1468-1331.2006.01686.x
- Fink MCDS, 2006, J INFECTION, V52, P30, DOI 10.1016/j.jinf.2005.02.015
- Jin Li, 1993, Journal of Medical Virology, V41, P11, DOI 10.1002/jmv.1890410104
- Shaffer K, 2006, J NEUROVIROL, V12, P39
- SUNDSFJORD A, 1994, J INFECT DIS, V169, P485
- Vidal José E, 2007, AIDS Res Ther, V4, P13, DOI 10.1186/1742-6405-4-13
- Weimberg GA, 2010, PEDIATR INFECT DIS J, V29, P257